Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of circulating miRNA in serving as age-related macular degeneration diagnostic markers

A technology of macular degeneration and markers, applied in the field of clinical diagnosis of molecular biology and medicine

Pending Publication Date: 2016-08-17
SHANGHAI TENTH PEOPLES HOSPITAL
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the application of the circulating miRNA of the present invention as a diagnostic marker for neovascular age-related macular degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of circulating miRNA in serving as age-related macular degeneration diagnostic markers
  • Application of circulating miRNA in serving as age-related macular degeneration diagnostic markers
  • Application of circulating miRNA in serving as age-related macular degeneration diagnostic markers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Microarray analysis of circulating miRNA expression profiles in patients with CNV AMD

[0037] 1. Materials and methods

[0038] 1. Research object

[0039] All the research subjects were from the patients who visited the Ophthalmology Department of the Tenth People's Hospital Affiliated to Tongji University from June 2012 to July 2012, and all the selected patients signed the informed consent.

[0040] 1.1 Experimental group (CNV AMD patients)

[0041] 1.1.1 Inclusion criteria

[0042] Patients with CNV age-related macular degeneration were diagnosed by fundus photography (FP), optical coherence tomography (OCT), and fluorescein fundus angiography (FFA), combined with vision changes.

[0043] CNV AMD diagnostic criteria:

[0044] (1) Corrected visual acuity <0.5, may have metamorphopsia, and gaze shadows in front of the eyes.

[0045] (2) Fundus photography: there are fused ill-defined drusen and subretinal hemorrhage in the macular area.

[0046] (3) O...

Embodiment 2

[0111] Example 2 Verification research of differential circulating miRNA

[0112] 1. Materials and methods

[0113] 1. Research Methods

[0114] All the research subjects were from patients who visited the Ophthalmology Department of the Tenth People's Hospital Affiliated to Tongji University from June 2012 to September 2012, and all signed the informed consent.

[0115] 1.1 Selection of clinical samples

[0116] 1.1.1 Experimental group

[0117] Inclusion criteria: through fundus photography (funds photography, FP), optical coherence tomography (optical coherence tomography, OCT), fluorescein angiography (fluorescein fundus angiography, FFA) examination, combined with vision changes, diagnosed as CNV age-related macular degeneration Patients. The inclusion criteria for neovascular AMD are the same as in Example 1, and the inclusion criteria for dry AMD are as follows:

[0118] (1) Visual acuity was not significantly affected, and the central visual acuity of all patients ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of circulating miRNA in serving as age-related macular degeneration diagnostic markers. Expression differences of miRNA between patients with neovascular AMD and patients with cataract are detected through a miRNA expression chip, ten pieces of miRNA are selected from all miRNA subjected to differential expression for verification, a sample is enlarged, special miRNA expression is conducted through a fluorescent quantitative PCR method, comparison is conducted on the content of different miRNA in the patients with AMD and a control group, and the feasibility of serving as the diagnostic markers is verified. It is displayed through ROC curve analysis that AUC of miR-27a-3p, AUC of miR-29b-3p and AUC of miR-195-5p are 79.1%, 72.7% and 70.7% respectively. It is shown that miR-27a-3p, miR-29b-3p and miR-195-5p can serve as the age-related macular degeneration diagnostic markers.

Description

technical field [0001] The invention relates to the technical field of clinical diagnosis of molecular biology and medicine, specifically, the application of circulating miRNA as a diagnostic marker for age-related macular degeneration. Background technique [0002] Age-related macular degeneration (AMD) is one of the most important causes of irreversible blindness in the elderly over 50 years old. According to a survey in the United States, the prevalence of AMD among people over the age of 40 is 9%. The epidemiological survey conducted in Handan and Beijing, China showed that the prevalence of AMD in the elderly was 3.1% and 5.5%, respectively. Aging, racial differences, heredity and smoking history are risk factors for AMD. Other factors such as obesity, heart disease and AMD have been reported inconsistently. Although there are dietary and lifestyle interventions, as well as the application of antioxidant drugs, intravitreal drug injections, laser photocoagulation, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 于靖吴岩任成达何梦梅危清泉
Owner SHANGHAI TENTH PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com